BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
23 sept. 2024 07h30 HE
|
BioAtla, Inc.
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and...
SKB264 Innovative Cancer Antibody Drug Conjugate Clinical Trials Efficacy Insight
19 sept. 2024 07h34 HE
|
KuicK Research
Delhi, Sept. 19, 2024 (GLOBE NEWSWIRE) -- SKB264, also known as MK-2870, is an innovative antibody-drug conjugate (ADC) targeting TROP2, currently being developed by Kelun Biotech in partnership...
Comstock Fuels Executes International License Agreement
18 sept. 2024 11h10 HE
|
Comstock Inc.
VIRGINIA CITY, Nev., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced execution of a binding agreement between Comstock Fuels Corporation...
Bispecific Antibody Drug Conjugates Clinical Trials Insight
17 sept. 2024 07h14 HE
|
KuicK Research
Delhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The global market for bispecific antibody-drug conjugates (BsADCs) has experienced remarkable expansion, attributed to their revolutionary capabilities in...
Adeia and LG Electronics Renew Media IP License Agreement
16 sept. 2024 07h18 HE
|
Adeia Inc.
SAN JOSE, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a leading technology company bringing technology from incubation to reality, today announced the renewal of its...
PodcastOne (Nasdaq: PODC) Acquires Exclusive Multi-Year Sales and Distribution Rights to Fool Coverage with Manny MUA and Laura Lee Podcast
13 sept. 2024 08h00 HE
|
PodcastOne
Fool Coverage Has 153 Episodes Since Its Launch in 2021 17th New Podcast Joining PodcastOne Network This Fiscal Year, 45th in Last 12 Months 3.8 Billion All-Time Network Downloads LOS...
Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Commercial Launch Market Forecast 2029
12 sept. 2024 07h49 HE
|
KuicK Research
Delhi, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029 Report: Report Answers...
Arteris Interconnect IP Selected by VeriSilicon for High-Performance SoC Design
10 sept. 2024 09h00 HE
|
Arteris, Inc.
CAMPBELL, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced that VeriSilicon...
Tenstorrent 和 Movellus 建立戰略合作關係，推動新一代小晶片為主的 AI 和高效能運算解決方案
09 sept. 2024 22h29 HE
|
Movellus
加州桑尼維爾, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Movellus 和 Tenstorrent 宣布，Tenstorrent 已經授權 Movellus 的數碼 IP 系列，作為其 AI 和高效能運算小晶片解決方案戰略合作的一部分。 是次合作旨在充分發揮兩家公司的優勢，開發小晶片為主的解決方案，以提升性能並優化功率。 Movellus Aeonic...
Tenstorrent 与 Movellus 达成战略合作，共同开发下一代基于芯粒的 AI 和 HPC 解决方案
09 sept. 2024 22h29 HE
|
Movellus
加州森尼维尔, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Movellus 和 Tenstorrent 宣布，作为战略合作的一部分，Tenstorrent 已获得 Movellus 数字 IP 系列的授权，用于其 AI 和 HPC 解决方案。 此次合作旨在利用双方公司的优势，开发基于芯粒的解决方案，以在优化功耗的同时增强性能。 Movellus Aeonic 数字...